TARA
$5.45
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Recent News
Protara Therapeutics: Q4 Earnings Snapshot
NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Tuesday reported a loss of $17.3 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 37 cents.
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, highlighting updated interim results from its ongoing non-muscle invasive bladder cancer (NMIBC) s
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Management said
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%
Protara Therapeutics, Inc. ( NASDAQ:TARA ) insiders who purchased shares in the last 12 months were richly rewarded...
Protara Therapeutics: Q3 Earnings Snapshot
NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Monday reported a loss of $13.3 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 31 cents.